Middle East & Africa Neuroendocrine Tumors Market to 2032
Overview
The Middle East & Africa Neuroendocrine Tumors Market is expected to reach a 248.73 USD Million by 2032 and is projected to grow at a CAGR of 15.04% from 2025 to 2032.
Revenue, 2024 (USD Million)
116.46
Forecast, 2032 (USD Million)
248.73
CAGR, 2024 - 2032
15.04%
Report Coverage
Middle East & Africa
Middle East & Africa Neuroendocrine Tumors Market 2018-2032 USD Million
Middle East & Africa Neuroendocrine Tumors Market, Key Findings (2025-2032)
Market Growth and Projections:
- Market Size (2024): 116.46 USD Million
- Projected Market Size (2032): 248.73 USD Million
- CAGR (2025-2032): 15.04%
Key Findings of Middle East & Africa Neuroendocrine Tumors Market
- The Middle East & Africa Neuroendocrine Tumors Market was valued at 116.46 USD Million in 2024.
- The Middle East & Africa Neuroendocrine Tumors Market is likely to grow at a CAGR of 15.04% during the forecast period of 2024 to 2032.
- In 2024, the Largest segment Non-Funtional NET in Classification Segment accounted for the largest share of the market with a revenue of 85.05 USD Million
- The fastest growing segment Oral in Route of Administration Segment grew Fastest with a CAGR of 24.51% during the forecast period from 2024 to 2032.
Middle East & Africa Neuroendocrine Tumors Market Scope
Middle East & Africa Neuroendocrine Tumors Market Segmentation & Scope
Route of Administration
- Parenteral
- Oral
End User
- Others
- Home Healthcare
- Radiation Centers
- Speciality Clinics
- Hospitals
Distribution Channel
- Others
- Online Pharmacy
- Retail Sales
- Hospital Pharmacy
- Direct Tender
Type
- Treatment
- Diagnosis
Classification
- Funtional NET
- Non-Funtional NET
Site
- Pancreas
- Lungs
- Gastrointestinal Tract (GI)
Grade
- Grade 1 (Low-Grade Tumor)
- Grade 3 (High-Grade Tumor)
- Grade 2 (Intermediate-Grade Tumor)
Middle East & Africa Neuroendocrine Tumors Market Data Coverage Insights
| Study Period | 2024-2032 |
| Base Year | 2020 |
| Unit | Revenue in USD Million |
| Market Value in 2024 | 116.46 USD Million |
| Market Value in 2032 | 248.73 USD Million |
| CAGR (2025-2032) | 15.04% |
| Historic Data | 2016-2023 |
| Market Segments Covered | Route of Administration,End User,Distribution Channel,Type,Classification,Site,Grade |
Regional Insights:
-
Leading Market (2024-2032): Middle East & Africa, leading in terms of revenue 116.46 USD Million in 2024
- Key Country: South Africa, leading in terms of revenue with value of 34.91 USD Million in 2024.
Segments and Scope
-
Middle East & Africa Neuroendocrine Tumors Market to 2032, By Route of Administration
- Oral is the largest segment in Middle East & Africa Neuroendocrine Tumors Market to 2032 with a revenue of 6.10 USD Million in the year 2024.
- Oral is the Fastest growing segment in Middle East & Africa Neuroendocrine Tumors Market to 2032 with a Growth rate of 24.51 % in forecast period 2025-2032.
-
Middle East & Africa Neuroendocrine Tumors Market to 2032, By End User
- Hospitals is the largest segment in Middle East & Africa Neuroendocrine Tumors Market to 2032 with a revenue of 46.45 USD Million in the year 2024.
- Speciality Clinics is the Fastest growing segment in Middle East & Africa Neuroendocrine Tumors Market to 2032 with a Growth rate of 14.32 % in forecast period 2025-2032.
-
Middle East & Africa Neuroendocrine Tumors Market to 2032, By Distribution Channel
- Direct Tender is the largest segment in Middle East & Africa Neuroendocrine Tumors Market to 2032 with a revenue of 43.04 USD Million in the year 2024.
- Direct Tender is the Fastest growing segment in Middle East & Africa Neuroendocrine Tumors Market to 2032 with a Growth rate of 16.46 % in forecast period 2025-2032.
-
Middle East & Africa Neuroendocrine Tumors Market to 2032, By Type
- Diagnosis is the largest segment in Middle East & Africa Neuroendocrine Tumors Market to 2032 with a revenue of 78.58 USD Million in the year 2024.
- Treatment is the Fastest growing segment in Middle East & Africa Neuroendocrine Tumors Market to 2032 with a Growth rate of 10.85 % in forecast period 2025-2032.
-
Middle East & Africa Neuroendocrine Tumors Market to 2032, By Classification
- Non-Funtional NET is the largest segment in Middle East & Africa Neuroendocrine Tumors Market to 2032 with a revenue of 85.05 USD Million in the year 2024.
- Non-Funtional NET is the Fastest growing segment in Middle East & Africa Neuroendocrine Tumors Market to 2032 with a Growth rate of 15.16 % in forecast period 2025-2032.
-
Middle East & Africa Neuroendocrine Tumors Market to 2032, By Site
- Gastrointestinal Tract (GI) is the largest segment in Middle East & Africa Neuroendocrine Tumors Market to 2032 with a revenue of 62.95 USD Million in the year 2024.
- Gastrointestinal Tract (GI) is the Fastest growing segment in Middle East & Africa Neuroendocrine Tumors Market to 2032 with a Growth rate of 15.75 % in forecast period 2025-2032.
-
Middle East & Africa Neuroendocrine Tumors Market to 2032, By Grade
- Grade 2 (Intermediate-Grade Tumor) is the largest segment in Middle East & Africa Neuroendocrine Tumors Market to 2032 with a revenue of 60.93 USD Million in the year 2024.
- Grade 2 (Intermediate-Grade Tumor) is the Fastest growing segment in Middle East & Africa Neuroendocrine Tumors Market to 2032 with a Growth rate of 15.71 % in forecast period 2025-2032.
Middle East & Africa Neuroendocrine Tumors Market Company Share Analysis
| Company Name |
|
||
| Mylan N.V. | |||
| Novartis AG | |||
| Lupin | |||
| Lilly | |||
| Thermo Fisher Scientific Inc. | |||
Middle East & Africa Neuroendocrine Tumors Market Geographical Sales Distribution, 2018-2032 USD Million
Middle East & Africa Neuroendocrine Tumors Market Company Profiling
Industry Related Reports
Frequently Asked Questions
The Middle East & Africa Neuroendocrine Tumors Market is segmented based on Segmentation Route of Administration,End User,Distribution Channel,Type,Classification,Site,Grade .
Middle East & Africa Neuroendocrine Tumors Market was valued at USD 116.46(Revenue in USD Million) in 2020.
Middle East & Africa Neuroendocrine Tumors Market is projected to grow at a CAGR of 15.04% during the forecast period of 2024 to 2032.
The Non-Funtional NET segment is expected to dominate the Middle East & Africa Neuroendocrine Tumors Market, holding a largest market share of 85.05 USD Million in 2024
Middle East & Africa Neuroendocrine Tumors Market Scope
Middle East & Africa Neuroendocrine Tumors Market Segmentation & Scope
Route of Administration
- Parenteral
- Oral
End User
- Others
- Home Healthcare
- Radiation Centers
- Speciality Clinics
- Hospitals
Distribution Channel
- Others
- Online Pharmacy
- Retail Sales
- Hospital Pharmacy
- Direct Tender
Type
- Treatment
- Diagnosis
Classification
- Funtional NET
- Non-Funtional NET
Site
- Pancreas
- Lungs
- Gastrointestinal Tract (GI)
Grade
- Grade 1 (Low-Grade Tumor)
- Grade 3 (High-Grade Tumor)
- Grade 2 (Intermediate-Grade Tumor)
Frequently Asked Questions
The Middle East & Africa Neuroendocrine Tumors Market is segmented based on Segmentation Route of Administration,End User,Distribution Channel,Type,Classification,Site,Grade .
Middle East & Africa Neuroendocrine Tumors Market was valued at USD 116.46(Revenue in USD Million) in 2020.
Middle East & Africa Neuroendocrine Tumors Market is projected to grow at a CAGR of 15.04% during the forecast period of 2024 to 2032.
The estimated market value of the Middle East & Africa Neuroendocrine Tumors Market for final year is USD 248.73 (USD Million).
Middle East & Africa Neuroendocrine Tumors Market Company Profiling
Frequently Asked Questions
The Middle East & Africa Neuroendocrine Tumors Market is segmented based on Segmentation Route of Administration,End User,Distribution Channel,Type,Classification,Site,Grade .
Middle East & Africa Neuroendocrine Tumors Market was valued at USD 116.46(Revenue in USD Million) in 2020.
Middle East & Africa Neuroendocrine Tumors Market is projected to grow at a CAGR of 15.04% during the forecast period of 2024 to 2032.
The estimated market value of the Middle East & Africa Neuroendocrine Tumors Market for final year is USD 248.73 (USD Million).
CHOOSE LICENCE TYPE
- 4200.00
- 3500.00
- 2000.00
- 5500.00
- 8500.00
HAVE A QUESTION?
Get expert advice on the right strategy for your business at no cost. We also offer customized subscription plans and affordable discounts for startups and universities.